Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
25 June 2021Website:
http://www.acurxpharma.comNext earnings report:
18 March 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | Thu, 21 Nov 2024 00:56:25 GMTDividend
Analysts recommendations
Institutional Ownership
ACXP Latest News
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP ) Q3 2024 Earnings Conference Call November 13, 2024 8:00 AM ET Company Participants Robert Shawah - Co-Founder & CFO David Luci - Co-Founder, President, CEO, Corporate Secretary & Director Conference Call Participants Thomas Yip - H.C. Wainwright John Stinson - Private Investor Operator Greetings, and welcome to the Acurx Pharmaceuticals, Inc. Third Quarter 2024 Results and Business Update Conference Call.
The data presented indicate a favorable gut bile acid profile which may contribute to ibezapostat's beneficial anti-recurrence effect in patients with C. difficile Infection (CDI) Ibezapolstat treatment of patients with CDI is associated with the restoration of beneficial bacterial classes in the gut Preparation continues to advance ibezapolstat into international Phase 3 clinical trials for treatment of C.
STATEN ISLAND, N.Y. , Oct. 16, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late- stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will discuss its third quarter 2024 financial results on Wednesday, November 13, 2024 at 8:00 am ET before the U.S. financial markets open.
The new series features continued broadcast television interviews, earned media placements, and a comprehensive outdoor advertising campaign. NEW YORK, NY / ACCESSWIRE / October 14, 2024 / New to The Street, one of the leading U.S. business television platforms, is pleased to announce the renewal of its media partnership with Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP), a late-stage biopharmaceutical company.
STATEN ISLAND, N.Y. , Aug. 9, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("we" or "Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the second quarter ended June 30, 2024.
Acurx Pharmaceuticals, Inc. (ACXP) Q4 2023 Earnings Call Transcript
STATEN ISLAND, N.Y. , March 4, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will release its fourth quarter and full year 2023 financial results on Monday, March 18, 2024, at 8:00 am ET before the U.S. financial markets open.
STATEN ISLAND, N.Y. , Jan. 23, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. ("Acurx" or the "Company") (NASDAQ: "ACXP"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections, today announced that David P.
Acurx shares opened ~25% lower on Jan 17th, after releasing positive data suggesting its C. diff antibiotic outperformed standard treatment in restoring the gut microbiome. The decline in share price since then may be due to misaligned investor expectations regarding the release of sustained clinical cure rates. Acurx is expected to release additional data, including 94-day sustained clinical cure rates, which could further establish its antibiotic as a preferred treatment for C. diff.
What type of business is Acurx Pharmaceuticals?
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
What sector is Acurx Pharmaceuticals in?
Acurx Pharmaceuticals is in the Healthcare sector
What industry is Acurx Pharmaceuticals in?
Acurx Pharmaceuticals is in the Biotechnology industry
What country is Acurx Pharmaceuticals from?
Acurx Pharmaceuticals is headquartered in United States
When did Acurx Pharmaceuticals go public?
Acurx Pharmaceuticals initial public offering (IPO) was on 25 June 2021
What is Acurx Pharmaceuticals website?
https://www.acurxpharma.com
Is Acurx Pharmaceuticals in the S&P 500?
No, Acurx Pharmaceuticals is not included in the S&P 500 index
Is Acurx Pharmaceuticals in the NASDAQ 100?
No, Acurx Pharmaceuticals is not included in the NASDAQ 100 index
Is Acurx Pharmaceuticals in the Dow Jones?
No, Acurx Pharmaceuticals is not included in the Dow Jones index
When was Acurx Pharmaceuticals the previous earnings report?
No data
When does Acurx Pharmaceuticals earnings report?
The next expected earnings date for Acurx Pharmaceuticals is 18 March 2025